Published: 7 March 2025
Author(s): Roberto Tonelli, Giulia Bruzzi, Riccardo Fantini, Luca Tabbì, Antonio Moretti, Francesco Livrieri, Ivana Castaniere, Stefania Cerri, Daniele Puggioni, Federico Guidotti, Gianluca Bellesia, Alessandro Marchioni, Enrico Clini
Issue: March 2025
Section: Original Article

In recent years, particularly following the COVID-19 pandemic, there has been increasing interest in non-invasive respiratory support (RS) to manage the acute hypoxemic respiratory failure (AHRF) [1–3]. This trend has extended beyond intensive care units (ICUs) to a variety of clinical settings, with high-flow nasal oxygen (HFNO) emerging as a promising option for respiratory support [4–6].

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.